Study guide
13.2 Stimulant Withdrawal, Craving & Contingency Management
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
13.2 Stimulant Withdrawal, Craving & Contingency Management
Key Takeaways Explain This Topic AI
Stimulant withdrawal is not life-threatening but produces a crash of hypersomnia, hyperphagia, profound dysphoria and suicidal ideation within 24 hours of the last dose.
Suicide risk during the stimulant crash is the principal safety concern, and DSM-5-TR lists dysphoric mood as a required feature of stimulant withdrawal.
Contingency management is the single most effective intervention for stimulant use disorder, with effect sizes larger than any pharmacotherapy tested to date.
Effective contingency management requires immediate, escalating, reset-on-relapse reinforcement tied to an objectively verified target such as a stimulant-negative urine sample.
Federal guidance has allowed higher incentive values than the historical 75 dollar per-patient-per-year ceiling that limited earlier programs, and low-value incentive schedules are a common reason contingency management fails in practice.
Last updated: September 2026
13.2 Stimulant Withdrawal, Craving & Contingency Management
Quick Answer: Stimulant withdrawal produces a crash beginning within hours: dysphoric mood (a required DSM-5-TR criterion) plus fatigue, vivid unpleasant dreams, insomnia or hypersomnia , increased appetite, and psychomotor retardation or agitation. It is not medically dangerous but carries genuine suicide risk . No medication is FDA-approved. Contingency management (CM) — tangible, immediate, escalating reinforcement for objectively verified stimulant-negative urine samples — is the most effective intervention available and should be offered to every patient with stimulant use disorder who can access it.
1. The Withdrawal Syndrome
Phase Timing Features
Crash Hours 0 to 72 (may extend to a week after a long methamphetamine binge) Profound fatigue, hypersomnia, hyperphagia, dysphoria, vivid dreams, irritability; suicidal ideation peaks here
Early withdrawal Days 3 to 10 Anhedonia, poor concentration, sleep dysregulation, intense craving triggered by cues
Protracted Weeks to months Anhedonia, reduced motivation, episodic craving that incubates rather than fades
DSM-5-TR stimulant withdrawal requires cessation or reduction of prolonged use, plus dysphoric mood and two or more of: fatigue; vivid unpleasant dreams; insomnia or hypersomnia; increased appetite; psychomotor retardation or agitation.
Exam trap: unlike alcohol and sedative withdrawal, stimulant withdrawal does not cause seizures, autonomic instability or delirium. A stimulant-using patient with tremor, tachycardia, diaphoresis and disorientation on day 2 of abstinence is withdrawing from something else — most often alcohol or a benzodiazepine — or has a medical cause.
Managing the crash
Safety first: assess suicidal ideation explicitly at each contact through the first week. The dysphoria is neurochemically driven and patients often describe it as worse than any depression they have experienced.
Sleep: allow the hypersomnia. Trazodone, mirtazapine or melatonin are reasonable if insomnia rather than hypersomnia predominates; avoid benzodiazepines and Z-drugs in a population with high sedative co-use.
Nutrition and hydration: patients are often profoundly depleted after a binge. Refeed, check electrolytes, and screen for rhabdomyolysis if the binge was prolonged.
Do not start an antidepressant reflexively. Most crash dysphoria resolves within one to two weeks. Persisting depressive symptoms beyond 2 to 4 weeks of abstinence warrant reassessment for an independent depressive disorder.
2. Contingency Management: Mechanism and Design
CM applies operant conditioning: a behavior that is objectively verified and immediately reinforced increases in frequency. In stimulant use disorder it consistently outperforms cognitive behavioral therapy, motivational interviewing, and every medication tested.
The design rules that determine whether CM works
Principle Requirement Common implementation failure
Objective target Reinforce a verifiable behavior — usually a stimulant-negative urine sample Reinforcing self-reported abstinence or session attendance only
Immediacy Deliver the reinforcer the same visit, within minutes of the result Mailing a gift card two weeks later
Frequency Test and reinforce 2 to 3 times weekly early in treatment Weekly or monthly testing, which lets use go undetected and unreinforced
Escalation Increase incentive value with each consecutive negative sample Flat, low-value incentives
Reset Return to the starting value after a positive or missed sample, with a rapid "recapture" path back up Permanent loss of accrued value, which drives dropout
Magnitude Total available value must be meaningful Historically many federal programs capped incentives near 75 dollars per patient per year, a value repeatedly shown to be too low; updated federal guidance permits substantially higher limits
Two common formats
Voucher-based reinforcement: each negative sample earns a voucher of escalating value, exchangeable for goods or services (never cash equivalents that facilitate use).
Prize-based (fishbowl) reinforcement: each negative sample earns draws from a bowl containing mostly small prizes with a few large ones, which lowers total program cost while preserving effect.
3. Other Non-Pharmacological Treatments With Evidence
Approach Description Evidence position
Community Reinforcement Approach plus vouchers (CRA + vouchers) Restructures the patient's environment so non-drug reinforcers — employment, relationships, recreation — compete with drug reinforcement, combined with CM Strongest combined behavioral package
The Matrix Model 16-week structured intensive outpatient program combining relapse prevention, family education, social support, urine testing and 12-step introduction; developed specifically for stimulant users Well-supported; the standard structured stimulant IOP
Cognitive behavioral therapy Functional analysis, coping skills, relapse prevention Effective, smaller effect than CM; durable gains after treatment ends
Exercise-based interventions Structured aerobic and resistance training Emerging evidence for reduced use and improved mood in residential settings
High-yield combination: CM produces the largest in-treatment effect, while CBT and CRA produce more durable post-treatment gains. Combining them is the defensible answer when a stem asks for the optimal non-pharmacological plan.
4. Addressing Common Staff Objections
The APRN frequently has to defend CM to colleagues and administrators. Three evidence-based responses:
"We are paying people not to use drugs." CM reinforces a verified biological outcome the same way a diabetes program reinforces glycemic targets. The reinforcer is contingent on the outcome, not on attendance.
"The effect disappears when incentives stop." In-treatment effects are large; post-treatment effects decay but remain above control. Pairing CM with CRA or CBT and with recovery supports extends the benefit.
"We cannot afford it." Prize-based schedules cost a fraction of voucher schedules, and stimulant-related emergency and inpatient utilization dwarfs incentive costs.